Collectively, these insights highlight opportunities to develop substrate‐selective PRMT1 inhibitors and refine preclinical models, bringing us closer to translating these findings into targeted therapies for metastatic cancer. The gene discussed is PRMT1; the disease is metastatic malignant neoplasm.